首页> Journal of pharmaceutical sciences> Ongoing Challenges to Develop High Concentration Monoclonal Antibody-based Formulations for Subcutaneous Administration: Quo Vadis?

Ongoing Challenges to Develop High Concentration Monoclonal Antibody-based Formulations for Subcutaneous Administration: Quo Vadis?

导出 LinkOut

翻译打印收藏纠错

第一作者： W,Jiskoot

第一单位： Coriolis Pharma Research GmbH, Fraunhoferstr. 18 b, 82152 Martinsried, Germany; Leiden Academic Center for Drug Research (LACDR), Leiden University, 2300 RA Leiden, the Netherlands.

作者： W,Jiskoot ^[1] ; Andrea,Hawe ^[2] ; Tim,Menzen ^[2] ; David B,Volkin ^[3] ; Daan J A,Crommelin ^[4]

作者单位： Coriolis Pharma Research GmbH, Fraunhoferstr. 18 b, 82152 Martinsried, Germany; Leiden Academic Center for Drug Research (LACDR), Leiden University, 2300 RA Leiden, the Netherlands. ^[1] Coriolis Pharma Research GmbH, Fraunhoferstr. 18 b, 82152 Martinsried, Germany. ^[2] Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS 66047, USA. ^[3] Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, 3584 CG Utrecht, the Netherlands. Electronic address: d.j.a.crommelin@uu.nl. ^[4]

关键词 Aggregation High concentration Monoclonal antibodies Protein engineering Subcutaneous Viscosity

医学主题词抗体, 单克隆(Antibodies, Monoclonal);生物利用度(Biological Availability);人类(Humans);纵向研究(Longitudinal Studies);皮下组织(Subcutaneous Tissue);黏度(Viscosity)

DOI 10.1016/j.xphs.2021.11.008

PMID 34813800

发布时间 2022-04-25

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交